Phaseline

Companies › Epygenix

Epygenix: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 1; Neurology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Clemizole HCl (EPX-100)–Phase 3Dravet Syndrome; Lennox Gastaut Syndrome; Healthy ParticipantsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07879170Clemizole HCl (EPX-100)Phase 1Healthy ParticipantsOtherDec 2026
NCT04462770Clemizole HCl (EPX-100)Phase 3Dravet SyndromeNeurologyApr 2027
NCT05066217Clemizole HCl (EPX-100)Phase 3Lennox Gastaut SyndromeNeurologyNov 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

GRIN Therapeutics Bracco Diagnostics NeuroDerm Cartesian Therapeutics Laboratorios Silanes S.A. de C.V.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.